SUBSCRIBE
SUBSCRIBE

CNS Pharmaceuticals, Inc.

NEWS
Image of Houston downtown park and skyline in the morning
Business
Houston’s Life Sciences Scene Continues Boosting Its Reputation
While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.
March 13, 2025
 · 
6 min read
 · 
Angela Gabriel
IN THE PRESS
Lone Star Bio
CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021
February 25, 2021
 · 
5 min read
Lone Star Bio
CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference
January 7, 2021
 · 
2 min read
Deals
CNS Pharmaceuticals Announced Pricing of $10.0 Million Public Offering
December 23, 2020
 · 
3 min read
Drug Development
CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET
December 18, 2020
 · 
2 min read
FDA
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin
December 17, 2020
 · 
5 min read
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
November 24, 2020
 · 
6 min read
Business
CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting
November 19, 2020
 · 
3 min read
Lone Star Bio
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin
November 17, 2020
 · 
5 min read
Drug Development
CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today
November 12, 2020
 · 
4 min read
Drug Development
CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review
November 9, 2020
 · 
4 min read
Load More
JOBS